BMY.RT Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Bristol-Myers Squibb Company and Encourages Investors to Contact the Firm

NEW YORK, NY / ACCESSWIRE / May 14, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Bristol-Myers Squibb Company ("Bristol-Myers" or "the Company") (NYSE:BMY.RT). Investors who purchased Bristol-Myers securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/bmy.

The investigation concerns whether Bristol-Myers and certain of its officers and/or directors have violated federal securities laws.

On November 20, 2019, BMS issued a press release announcing the completion of its merger with Celgene Corporation ("Celgene"). Under the terms of the merger, Celgene shareholders received for each Celgene share: 1.00 share of Bristol-Myers Squibb common stock; $50.00 in cash without interest; and one tradeable Contingent Value Right ("CVR"). BMS's press release advised investors that each CVR "will entitle the holder to receive a payment of $9.00 in cash if certain future regulatory milestones are achieved." On November 21, 2019, the CVRs began trading on the New York Stock Exchange under the ticker symbol "BMY.RT." On May 6, 2020, BMS issued a press release announcing, in relevant part, that "the U.S. Food and Drug Administration (FDA) has extended the action date by three months for the biologics license application (BLA) for lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy for the treatment of adults with relapsed or refractory (R/R) large B-cell lymphoma after at least two prior therapies. The new Prescription Drug User Fee Act (PDUFA) action date set by the FDA is November 16, 2020." Then, on May 13, 2020, BMS issued a press release announcing receipt of "a Refusal to File letter from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for idecabtagene vicleucel (ide-cel; bb2121) for patients with heavily pre-treated relapsed and refractory multiple myeloma, which was submitted in March 2020." Following each of the foregoing disclosures, the value of BMS's tradeable CVRs fell sharply, damaging investors.

If you are aware of any facts relating to this investigation, or purchased Bristol-Myers shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/bmy. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

View source version on accesswire.com:
https://www.accesswire.com/589889/BMYRT-Investor-Alert-Bronstein-Gewirtz-Grossman-LLC-Announces-Investigation-of-Bristol-Myers-Squibb-Company-and-Encourages-Investors-to-Contact-the-Firm